HitGen Inc. (SHA:688222)

China · Delayed Price · Currency is CNY

36.16

-2.54 (-6.56%)

At close: Aug 21, 2026

59.15% (1Y)

Market Cap	14.49B +59.6%
Revenue (ttm)	579.37M +35.9%
Net Income	122.72M +86.8%
EPS	0.30 +73.8%
Shares Out	400.68M
PE Ratio	120.31
Forward PE	106.35
Dividend	0.13 (0.37%)
Ex-Dividend Date	Jun 18, 2026

Volume	24,474,052
Open	37.16
Previous Close	38.70
Day's Range	35.66 - 38.00
52-Week Range	21.46 - 42.98
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multipl... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 546

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688222

Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 109.51 million, an increase of 113.22%.

Financial Statements